After 3 years of treatment, infliximab was temporarily withdrawn ... The most common adverse events were infections and injection-site reactions; these events were also the most frequent reasons ...

Get detailed information on Infliximab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

ZYMFENTRA is the first FDA-approved subcutaneous infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease. ZYMFENTRA is a ...

ZYMFENTRA is the first FDA-approved subcutaneous infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.

Korean drugmaker Celltrion plans to achieve annual sales of 5 trillion won ($3.58 billion) next year, driven by the growth of ...